{
    "clinical_study": {
        "@rank": "56877", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Each patient will receive a volume of placebo based on weight"
            }, 
            {
                "arm_group_label": "EPI-743 15 mg/kg", 
                "arm_group_type": "Active Comparator", 
                "description": "Each subjects dose will be based on their weight. 15 mg/kg with a maximum dose of 200 mg per dose, t.i.d., will be administered in this treatment arm."
            }, 
            {
                "arm_group_label": "EPI-743 5 mg/kg", 
                "arm_group_type": "Active Comparator", 
                "description": "Each subjects dose will be based on their weight. 5 mg/kg with a maximum dose of 100 mg per dose, t.i.d., will be administered in this treatment arm."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects of EPI-743 in children with Leigh\n      syndrome on disease severity, neuromuscular function, respiratory function, disease\n      morbidity and mortality and disease associated biomarkers."
        }, 
        "brief_title": "Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Leigh Syndrome", 
        "condition_browse": {
            "mesh_term": "Leigh Disease"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to evaluate the effects of EPI-743 in patient with Leigh\n      syndrome on disease severity, neuromuscular function, respiratory function, disease\n      morbidity and mortality and biomarkers associated with the disease.\n\n      This study is a six month prospective randomized double-blind, placebo-controlled trial with\n      a six month extension phase of two dose levels of EPI743. The planned enrollment is for\n      approximately 30 children with genetically confirmed Leigh syndrome. After 6 months of\n      treatment, those children that were randomized to the placebo treatment arm will be\n      re-randomized to one of the 2 active treatment arms."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical and MRI diagnosis of Leigh syndrome\n\n          -  Moderate disease severity based on NPMDS score\n\n          -  Age under 18 years\n\n          -  Documented evidence of disease progression within 12 month of enrollment\n\n          -  Availability of MRI that confirms necrotizing encephalopathy\n\n          -  Patient or guardian able to consent and comply with protocol requirements\n\n          -  Abstention from Coenzyme Q10, Vitamins C & E, lipoic acid and Idebenone\n\n        Exclusion Criteria:\n\n          -  Allergy to EPI-743, Vitamin E or sesame oil\n\n          -  History of bleeding abnormalities or abnormal PT/PTT\n\n          -  Diagnosis of concurrent inborn error of metabolism\n\n          -  Previous tracheostomy\n\n          -  Ventilator dependent or use of noninvasive ventilatory support w/in 1 month of\n             enrollment\n\n          -  LFTs greater than 2 times ULN\n\n          -  Renal insufficiency\n\n          -  End stage cardiac failure\n\n          -  Fat malabsorption syndrome\n\n          -  Use of anticoagulant medications\n\n          -  Abstention from Botox for 6 months prior to enrollment and for duration of study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721733", 
            "org_study_id": "EPI743-12-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "EPI-743 15 mg/kg", 
                "intervention_name": "EPI-743 15 mg/kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "EPI-743 5 mg/kg", 
                "intervention_name": "EPI-743 5 mg/kg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "EPI743", 
            "Leigh syndrome", 
            "respiratory chain disease", 
            "mitochondrial disorders"
        ], 
        "lastchanged_date": "October 23, 2013", 
        "link": {
            "description": "Edison Pharmaceuticals Web Site", 
            "url": "http://www.edisonpharma.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94304"
                    }, 
                    "name": "Stanford University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Akron", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44308"
                    }, 
                    "name": "Akron Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Baylor College of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98105"
                    }, 
                    "name": "Seattle Children's Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2B Randomized, Placebo Controlled, Double Blind Clinical Trial of EPI-743 in Children With Leigh Syndrome", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline to six months will be compared between subjects in active treatment group and placebo group", 
            "measure": "Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) Sections 1-3", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721733"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Gross Motor Function Measure; Barry Albright Dystonia Scale", 
                "measure": "Neuromuscular function", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Need for tracheostomy", 
                "measure": "Respiratory function", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Total number of hospitalizations", 
                "measure": "Disease morbidity", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Blood levels of glutathione will be compared between placebo and treatment group", 
                "measure": "Glutathione cycle biomarkers", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Number of dose limiting serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Number of deaths", 
                "measure": "Mortality", 
                "safety_issue": "No"
            }
        ], 
        "source": "Edison Pharmaceuticals Inc", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Axio Research. LLC", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Biosoteria", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Edison Pharmaceuticals Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}